Document is current
Any future updates will be listed below
-
Authors
Vrentzos, Emmanouil
Ikonomidis, Ignatios
Pavlidis, George
Katogiannis, Konstantinos
Korakas, Emmanouil
Kountouri, Aikaterini
Pliouta, Loukia
Michalopoulou, Eleni
Pelekanou, Emilia
Boumpas, Dimitrios
Lambadiari, Vaia
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05941910 at ClinicalTrials.govDocuments that mention this clinical trial
Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial
https://doi.org/10.1186/s12933-024-02326-8
- License Information
-
More Information
Article History
Received: 17 March 2024
Accepted: 18 June 2024
First Online: 10 July 2024
Declarations
:
: <b>Not applicable</b>.
: V.L. has given lectures, attended conferences and participated in trials sponsored by Novo Nordisk, Sanofi-Aventis, Novartis, Astrazeneca, BoehringerIngelheim, MSD, GSK, Vianex, Elli Lilly, ELPEN, Mylan and Aegereon. The rest of the authors declare that they have no competing interests.
: The Institutional Review Board of University General Hospital “Attikon” gave their approval to the study protocol (Approval number: 441/13-07-2022). All participants provided written consent to participate.
